
Perrigo Company plc
PRGONYSEHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$14.25
+$0.55 · +4.01%
PRGO company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
65
Undervalued
Momentum
26
Weakening
Sentiment
56
Mixed
Risk resilience
42
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePerrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- IE
- CEO
- Albert A. Manzone
- Listed since
- Dec 17, 1991
- Employees
- 8,100
Market position
Day range
Current $14.25
52-week range
Current $14.25
- Open
- $13.68
- Previous close
- $13.70
- Volume
- 2.58M
- 0.84× average
- Average volume
- 3.08M
- Average daily volume
- Market cap
- 1.97B USD
- Beta
- 0.54
- Market reference 1
- 50-day average
- $11.0864
- +28.54% above average
- 200-day average
- $12.216
- +16.65% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 5.37B USD
- EV / EBITDA
- -6.72×
- Earnings yield
- -73.93%
- Free cash flow yield
- 7.53%
Profitability & efficiency
- Return on equity
- -48.56%
- Return on assets
- -16.70%
- Return on invested capital
- 4.53%
Financial health
- Current ratio
- 2.76×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.25B USD | 4.37B USD | 4.66B USD | 4.45B USD | 4.14B USD |
| Cost of goods sold | 2.76B USD | 2.83B USD | 2.98B USD | 3B USD | 2.72B USD |
| Gross profit | 1.49B USD | 1.54B USD | 1.68B USD | 1.46B USD | 1.42B USD |
| Research and development | 95.4M USD | 112.2M USD | 122.5M USD | 123.1M USD | 122M USD |
| Selling, general, and administrative | 526.5M USD | 1.11B USD | 1.27B USD | 1.21B USD | 1.11B USD |
| Operating expenses | 1.15B USD | 1.43B USD | 1.53B USD | 1.38B USD | 1.01B USD |
| Interest expense | 162.5M USD | 187.8M USD | 173.8M USD | 156M USD | 125M USD |
| Depreciation and amortization | 337.5M USD | 325.9M USD | 359.5M USD | 338.6M USD | 312.2M USD |
| Operating income | 343.3M USD | 112.9M USD | 151.9M USD | 78.9M USD | 410.4M USD |
| Net income | −1.43B USD | −171.8M USD | −12.7M USD | −140.6M USD | −68.9M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -10.29
- FY2025
- Latest fiscal-year revenue
- 4.25B USD
- FY2025 · -2.75% year over year
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
36 ratingsPRGO news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 26, 1993 | 2:1 | — | — |
Effective Aug 26, 1993
2:1
PRGO peers
ETFs holding PRGO
Funds reporting this stock among their holdings, ordered by reported position size.
Invesco High Yield Equity Dividend Achievers ETFPEY52.41M4.46%1.18B USD0.54%$25.18+0.26%
Vanguard Morningstar Total Stock Market ETFVTI44.82M0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB32.22M0.02%183.4B USD0.03%$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR20.42M0.03%68.3B USD0.05%$249.18+0.68%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM17.7M0.10%17.03B USD0.03%$57.28+0.61%
State Street SPDR S&P Dividend ETFSDY17.27M0.08%22.07B USD0.35%$158.44+0.23%
Invesco Pharmaceuticals ETFPJP16.53M3.13%535.56M USD0.57%$130.06+0.91%
Global X - SuperDividend ETFSDIV16.19M1.30%1.24B USD0.58%$24.92+0.69%
Invesco High Yield Equity Dividend Achievers ETFPEY- Market value
- 52.41M
- Weight
- 4.46%
- AUM
- 1.18B USD
- Expense ratio
- 0.54%
- Price / 1D
- $25.18+0.26%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 44.82M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 32.22M
- Weight
- 0.02%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 20.42M
- Weight
- 0.03%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $249.18+0.68%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM- Market value
- 17.7M
- Weight
- 0.10%
- AUM
- 17.03B USD
- Expense ratio
- 0.03%
- Price / 1D
- $57.28+0.61%
State Street SPDR S&P Dividend ETFSDY- Market value
- 17.27M
- Weight
- 0.08%
- AUM
- 22.07B USD
- Expense ratio
- 0.35%
- Price / 1D
- $158.44+0.23%
Invesco Pharmaceuticals ETFPJP- Market value
- 16.53M
- Weight
- 3.13%
- AUM
- 535.56M USD
- Expense ratio
- 0.57%
- Price / 1D
- $130.06+0.91%
Global X - SuperDividend ETFSDIV- Market value
- 16.19M
- Weight
- 1.30%
- AUM
- 1.24B USD
- Expense ratio
- 0.58%
- Price / 1D
- $24.92+0.69%
Continue in GoAI
Research PRGOresearch.disclaimer











